Figure 2.
Tornado diagram of one-way sensitivity analyses with greatest influence parameters in (A) Durc versus Pemc, (B) Nivc versus Pemc and (C) Nivc versus Atec. Durc, durvalumab plus chemotherapy; Nivc, nivolumab plus chemotherapy; Pemc, pembrolizumab plus chemotherapy; Atec, atezolizumab plus chemotherapy; HR, hazard ratio; INMB, incremental net-monetary benefit; PFS, progression-free survival; PD, progressed disease; OS, overall survival.